Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan;50(2):242-246.
doi: 10.1007/s00259-022-05934-2.

An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine

EANM Radiobiology Working Group:; Jean-Pierre Pouget  1 , Mark Konijnenberg  2 , Uta Eberlein  3 , Gerhard Glatting  4 , Pablo Minguez Gabina  5 , Ken Herrmann  6 , Søren Holm  7 , Lidia Strigari  8 , Fijs W B van Leeuwen  9 , Michael Lassmann  3
Affiliations
Editorial

An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine

EANM Radiobiology Working Group: et al. Eur J Nucl Med Mol Imaging. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

M.L. has received research grants by IPSEN Pharma and Nordic Nanovector.

K.H. reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal and fees from Janssen, outside the submitted work.

J-P.P., M.K., U.E., G.G., P.M.G., S.H., L.S., and F.v.L. have no conflicts of interest to declare.

M.L. is member of the EANM board.

The following authors are members of the EANM committees:

• Radiation Protection (U.E., S.H.)

• Oncology (M.K., K.H.)

• Dosimetry (P.M.G.)

• Translational Molecular Imaging & Therapy (J-P.P., F.v.L.)

References

    1. European Association of Nuclear Medicine (EANM), European Federation of Organizations for Medical Physics (EFOMP), European Federation of Radiographer Societies (EFRS), European Society of Radiology (ESR), European Society for Radiotherapy and Oncology (ESTRO) Common strategic research agenda for radiation protection in medicine. Insights Imaging. 2017;8:183–97. doi: 10.1007/s13244-016-0538-x. - DOI - PMC - PubMed
    1. Harrison RM, Ainsbury E, Alves J, Bottollier-Depois J-F, Breustedt B, Caresana M, et al. EURADOS strategic research agenda 2020: vision for the dosimetry of ionising radiation. Radiat Prot Dosimetry. 2021;194:42–56. doi: 10.1093/rpd/ncab063. - DOI - PMC - PubMed
    1. Sgouros G, Bolch WE, Chiti A, Dewaraja YK, Emfietzoglou D, Hobbs RF, et al. ICRU report 96, dosimetry-guided radiopharmaceutical therapy. JICRU. 2021;21:1–212.
    1. Yonekura Y, Mattsson Flux G, Bolch WE, Dauer LT, Fisher DR, et al. Radiological protection in therapy with radiopharmaceuticals. ICRP Publ 140. 2019;48:5–95. - PubMed
    1. Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L, et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging. 2021;48:3365–3377. doi: 10.1007/s00259-021-05345-9. - DOI - PMC - PubMed

Publication types

LinkOut - more resources